Carbamazepine-10,11 Epoxide

CPT: 80161
8016180161
8016180161
Updated on 12/4/2022
Print Share

Synonyms

  • Carbatrol®
  • CBZ
  • Epitol®
  • Epoxide
  • Tegretol®
  • Carbatrol®
  • Epitol®
  • Equetro®
  • Tegretol®
  • Tegretol®-XR
  • Carbatrol®
  • CBZ
  • Epitol®
  • Epoxide
  • Tegretol®

Expected Turnaround Time

2 days

5 - 8 days

2 days


Related Documents


Specimen Requirements


Specimen

Serum or plasma


Volume

2 mL

1 mL

2 mL


Minimum Volume

0.5 mL


Container

Red-top (no additive) tube or green-top (heparin) tube; gel-barrier tubes not recommended

Red-top tube or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant. Transfer separated serum or plasma to a plastic transport tube.

Red-top (no additive) tube or green-top (heparin) tube; gel-barrier tubes not recommended


Collection

Transfer separated serum or plasma to a plastic transport tube.

Trough: immediately prior to net dose. Due to variability of absorption, the trough level may not represent the lowest drug level during the dosing interval; therefore, in some patients, multiple determinations may be necessary.

Transfer separated serum or plasma to a plastic transport tube.


Storage Instructions

Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen.

Room temperature

Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen.


Test Details


Use

Therapeutic drug management

Carbamazepine-10,11 epoxide has anticonvulsant activity similar to that of the parent compound. The half-life averages six hours and is 60% bound to protein.1 This heterocyclic (iminostilbene) compound has potent antiepileptic properties and is effective alone or with other antiepileptic drugs in partial seizures, especially complex partial seizures, generalized tonic-clonic seizures, and combinations of these seizure types. Carbamazepine generally is ineffective for absence, myoclonic, and atonic seizures. In children with symptomatic generalized epilepsy and continuous spike-and-wave discharge, these seizure types may develop (or tonic-clonic seizures may increase in frequency) with the use of carbamazepine.

Therapeutic drug management


Limitations

In-house validated method

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

In-house validated method


Methodology

Liquid chromatography/tandem mass spectrometry (LC/MS-MS)


Reference Interval

Suggested range: 0.4−4.0 μg/mL


LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
716803 Carbamazepine-10,11 Epoxide 9415-1 716804 Carbamazepine-10,11 Epoxide mcg/mL 9415-1

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf